Phase 2Recruiting
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
- Sponsor
- University of Wisconsin, Madison (Academic or other)
- Enrolment
- 50 planned
- Conditions
- Fibrosis Lung
- Interventions
- FAPI tracer; PET/MRI
- Ages
- adults, older adults
- Registry
- NCT06940427
From the registry
The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity. Participants will undergo up to 4 PET/MRI scans using the FAPI radiotracer.
Primary outcomes
- Change in FAPI uptake